Cargando…
A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation
A tuberculosis (TB) vaccine consisting of a recombinant fusion protein (H4) and a novel TLR9 adjuvant (IC31) is in clinical development. To better understand the H4-IC31 ratio, we measured the binding capacity of IC31 for H4 protein and immunized mice with formulations that contained limiting to exc...
Autores principales: | Aboutorabian, Sepideh, Hakimi, Jalil, Boudet, Florence, Montano, Sandrine, Dookie, Annie, Roque, Cristopher, Ausar, Salvador F, Rahman, Nausheen, Brookes, Roger H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514381/ https://www.ncbi.nlm.nih.gov/pubmed/25997147 http://dx.doi.org/10.1080/21645515.2015.1023970 |
Ejemplares similares
-
Screening vaccine formulations for biological activity using fresh human whole blood
por: Brookes, Roger H, et al.
Publicado: (2014) -
Is cough really necessary for TB transmission?
por: Patterson, Benjamin, et al.
Publicado: (2019) -
Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose
por: Aagaard, Claus, et al.
Publicado: (2009) -
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area
por: Hussein, Jemal, et al.
Publicado: (2018) -
A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques
por: Pavot, Vincent, et al.
Publicado: (2021)